Compound profile
Follistatin-344
EmergingAlso known as: FS-344 · Follistatin
A naturally occurring protein that neutralizes myostatin and related growth-inhibiting signals, allowing muscle to grow beyond its normal ceiling. The systemically circulating isoform used in early-phase gene therapy trials for muscular dystrophy, now also sold as a standalone research peptide with no human data in that injectable form.
Overview
Follistatin is a naturally occurring protein the body already produces, and FS-344 refers to a specific splice variant, 344 amino acids long, that circulates systemically rather than staying anchored near the cell surface like some other follistatin isoforms. Its biological role is to bind and block myostatin, activin, and other TGF-beta family signals that normally act as brakes on muscle growth, which is why animal studies removing or blocking myostatin consistently show dramatic, sometimes extreme, increases in muscle mass.
The most substantial human research on follistatin comes from gene therapy, not injectable peptide, work. Researchers delivered the FS-344 gene directly into muscle tissue using an adeno-associated virus vector in small, early-phase trials for Becker muscular dystrophy and inclusion body myositis, where patients' own muscle cells were engineered to produce the protein locally over an extended period. Those trials reported improved six-minute walk test distances in some patients along with favorable muscle biopsy findings, though results were mixed across participants and the studies were small.
The injectable, recombinant peptide sold as "Follistatin-344" in research-chemical markets is a different delivery method entirely from the gene therapy actually tested in humans, and that distinction matters: there is no published human trial of injected recombinant follistatin protein for muscle building in healthy adults.
Mechanism (plain language)
Binds and neutralizes myostatin, activin A, and related TGF-beta superfamily signals that normally suppress muscle growth, removing a molecular brake and allowing greater muscle hypertrophy and, in animal models, hyperplasia.
How it works
Myostatin and activin normally signal through activin type II receptors on muscle cells to restrain growth, acting as a built-in ceiling on how large muscle fibers and how numerous they become. Follistatin works upstream of that receptor, binding myostatin and activin directly in circulation and preventing them from ever reaching their receptor, which effectively removes the brake rather than overriding it downstream.
Animal studies removing myostatin genetically, or blocking it with follistatin gene therapy or recombinant protein, report dramatic muscle mass increases, in the range of 20 to 40 percent in some rodent, sheep, and dog studies, with effect sizes larger than seen with anabolic steroids in comparable animal models. In the human gene therapy trials, delivering the FS-344 gene into muscle tissue let patients' own cells produce and secrete the protein locally over an extended period, which is a fundamentally different pharmacokinetic profile than injecting a bolus of recombinant peptide that clears the body within hours.
What research suggests
Preclinical animal studies robustly support myostatin inhibition as a driver of muscle growth. Human evidence is limited to a handful of small, early-phase gene therapy trials in muscle-wasting diseases, with mixed individual results and no data at all on the injectable protein form marketed as a research peptide.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Dramatic muscle mass increases in animal models
Studies blocking myostatin with follistatin gene therapy or recombinant protein report muscle mass increases in the range of 20 to 40 percent across rodent, sheep, and dog models, larger than typically reported with anabolic steroids in comparable animal studies.
Functional improvement in early-phase human gene therapy trials
In the Becker muscular dystrophy trials, several patients receiving AAV-delivered FS-344 gene therapy showed improved six-minute walk test distances and reduced muscle fibrosis on biopsy, though results were mixed across the small cohort.
Uncertainties & risks
The human trials that exist used a gene therapy delivery method, not the injectable protein sold commercially, so those results do not directly validate the product most people encounter. Long-term effects of sustained myostatin inhibition in healthy adults, including on tendons, connective tissue, and cardiac muscle, remain an open research question.
It is important to separate what has been tested from what is sold: the follistatin gene therapy trials in Becker muscular dystrophy and inclusion body myositis used an AAV vector to make patients' own muscle produce the protein over time, a method with its own distinct safety profile from injecting recombinant follistatin peptide directly, which has never been tested in a published human trial for muscle building. Even within the animal literature, myostatin inhibition's dramatic effects on skeletal muscle raise unanswered questions about proportional effects on tendons and connective tissue, which do not necessarily strengthen at the same rate as muscle, a mismatch some researchers flag as a theoretical injury risk. The recombinant injectable peptide is unregulated and unapproved, with no independent verification of purity or dosing.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.